相关实验视频

Updated: Jan 14, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

电针治疗结直肠癌中化疗诱导的胃肠道症状:多中心,三臂,随机对照试验的协议

Zi-Wen Chen^1,2, Tao Xu³, Zi-Han Yin^1,2

¹Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610075, China.

International journal of colorectal disease

|October 27, 2025

概括

电针 (EA) 可以有效地减少结直肠癌 (CRC) 患者的化疗诱导的胃肠道 (GI) 毒性. 本研究研究EA作为一种非药物治疗方法来改善生活质量和化疗坚持.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
综合医学是一个整体的医学.

背景情况:

结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
化学治疗常常导致严重的胃肠道 (GI) 毒性,影响患者的生活质量.
缺乏有效的非药物干预方法来治疗化疗引起的胃肠道症状.

研究的目的:

评估电针 (EA) 在缓解化学疗法诱导的肠胃功能障碍中对CRC患者的疗效.
评估EA作为标准癌症治疗的安全,非药物补充剂的潜力.

主要方法:

一个多中心,三臂随机受控试验 (RCT) 涉及231名CRC患者,患有化疗后的胃肠道症状.
干预包括电针 (EA) 加标准护理,假针 (SA) 加标准护理,或单独标准护理.
主要结果:胃肠道症状评分表 (GSRS) 总分数的变化;次要结果:GSRS分量表,FACT-C,SAS/SDS分数.

主要成果:

这个部分不在所提供的摘要中.
该研究旨在产生关于EA有效性的高质量证据.
结果将使用意图治疗线性混合效应模型进行分析.

结论:

电针 (EA) 显示出作为一种非药物干预的承诺,用于治疗结直肠癌 (CRC) 患者的化疗诱导的肠道毒性.
如果有效,EA可以减少症状负担并改善患者对化疗的坚持.
本RCT旨在提供强有力的证据,用于将EA纳入标准CRC护理中.

关键词:

化疗化疗是一种化学疗法.结肠直肠癌是一种癌症.电 ?? 疗法是一种电疗法.胃肠道毒性胃肠道毒性随机对照试验是随机对照试验.

更多相关视频

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...